Naproxen Prices Climbs 1.4% in October as High Demand and Low Supply Intersect

Naproxen Prices Climbs 1.4% in October as High Demand and Low Supply Intersect

Li Hua 07-Nov-2025

The prices of Naproxen have climbed in October 2025 across the major markets of the globe after a stable September. The increase in the market value was driven by a convergence of firm downstream demand and rising production costs. The pharmaceutical formulators and OTC manufacturers have increased procurement volumes to replenish their inventories to meet the sustained end-user demand for Naproxen-containing formulations. The demand for the medications with Naproxen typically increases in cooler months. The strategic pricing by the suppliers which was aimed at protecting margins amid tightening stocks with accelerated buying by downstream purchasers to secure supply for upcoming production cycles have created an upward pressure on the market values of Naproxen. The higher feedstock costs for acetic anhydride in major manufacturing regions have raised the input costs which reduced the willingness of suppliers to sell at previous levels. The result was a synchronized rise in prices across key markets in October as immediate demand-side tightness have faced cost-side constraints.

Selenis has effectively manufactured recycled PET chips using terephthalic acid sourced from Circ®, a textile-to-textile recycler based in Virginia. The chip production took place through a series of batches at Selenis' pilot plant in San-Giorgio, Italy. By utilizing inputs recovered from polycotton textile waste, Selenis has created high-quality PET chip, which has been further processed into DTY yarn. This yarn will play a crucial role in product development as Circ prepares for additional capsule launches. Selenis is leveraging the success of this initial collaboration phase and is committed to advancing towards an offtake partnership to support Circ's inaugural industrial facility. Eduardo Santos, Head of Corporate Strategy at Selenis, remarked that the monomer synthesis showed a performance comparable to virgin terephthalic acid. He expressed optimism about the consistent quality of Circ's monomer output and anticipated future commercial success. Santos pointed out that the Circ partnership complements Selenis's existing mission and goals for a more sustainable textile industry. He further stated their anticipation of expanding upon this collaboration and providing support for Circ's forthcoming commercial production trials.
Tags:

Naproxen

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.